734 related articles for article (PubMed ID: 23887202)
21. Wide-field fundus autofluorescence imaging to evaluate retinal function in patients with retinitis pigmentosa.
Ogura S; Yasukawa T; Kato A; Usui H; Hirano Y; Yoshida M; Ogura Y
Am J Ophthalmol; 2014 Nov; 158(5):1093-8. PubMed ID: 25062603
[TBL] [Abstract][Full Text] [Related]
22. Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis.
Telek HH; Yesilirmak N; Sungur G; Ozdemir Y; Yesil NK; Ornek F
Doc Ophthalmol; 2017 Dec; 135(3):187-194. PubMed ID: 28852896
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Maculopathy in Patients Using Hydroxychloroquine.
Uğurlu A; Aslanova M; Cebeci Z; Kır Mercül N
Turk J Ophthalmol; 2019 Jun; 49(3):149-153. PubMed ID: 31245977
[TBL] [Abstract][Full Text] [Related]
24. Retinal toxicity found in a patient with systemic lupus erythematosus prior to 5 years of treatment with hydroxychloroquine.
Chiang E; Jampol LM; Fawzi AA
Rheumatology (Oxford); 2014 Nov; 53(11):2001. PubMed ID: 25172940
[No Abstract] [Full Text] [Related]
25. The optical coherence tomography angiography findings of rheumatoid arthritis patients taking hydroxychloroquine.
Ozek D; Onen M; Karaca EE; Omma A; Kemer OE; Coskun C
Eur J Ophthalmol; 2019 Sep; 29(5):532-537. PubMed ID: 30229672
[TBL] [Abstract][Full Text] [Related]
26. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.
Melles RB; Marmor MF
JAMA Ophthalmol; 2014 Dec; 132(12):1453-60. PubMed ID: 25275721
[TBL] [Abstract][Full Text] [Related]
27. Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy.
Marmor MF; Melles RB
Ophthalmology; 2014 Jun; 121(6):1257-62. PubMed ID: 24439759
[TBL] [Abstract][Full Text] [Related]
28. Hydroxychloroquine retinopathy: an emerging problem.
Latasiewicz M; Gourier H; Yusuf IH; Luqmani R; Sharma SM; Downes SM
Eye (Lond); 2017 Jun; 31(6):972-976. PubMed ID: 28186509
[TBL] [Abstract][Full Text] [Related]
29. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine.
Kellner U; Renner AB; Tillack H
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3531-8. PubMed ID: 16877425
[TBL] [Abstract][Full Text] [Related]
30. Multimodal imaging in deferoxamine retinopathy.
Viola F; Barteselli G; DellʼArti L; Vezzola D; Mapelli C; Villani E; Ratiglia R
Retina; 2014 Jul; 34(7):1428-38. PubMed ID: 24378427
[TBL] [Abstract][Full Text] [Related]
31. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography.
Lyons JS; Severns ML
Am J Ophthalmol; 2007 May; 143(5):801-809. PubMed ID: 17336914
[TBL] [Abstract][Full Text] [Related]
32. A novel method for screening the multifocal electroretonogram in patients using hydroxychloroquine.
Chang WH; Katz BJ; Warner JE; Vitale AT; Creel D; Digre KB
Retina; 2008; 28(10):1478-86. PubMed ID: 18997610
[TBL] [Abstract][Full Text] [Related]
33. Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss.
Stepien KE; Han DP; Schell J; Godara P; Rha J; Carroll J
Trans Am Ophthalmol Soc; 2009 Dec; 107():28-33. PubMed ID: 20126479
[TBL] [Abstract][Full Text] [Related]
34. Use of OCT Retinal Thickness Deviation Map for Hydroxychloroquine Retinopathy Screening.
Kim KE; Ahn SJ; Woo SJ; Park KH; Lee BR; Lee YK; Sung YK
Ophthalmology; 2021 Jan; 128(1):110-119. PubMed ID: 32553941
[TBL] [Abstract][Full Text] [Related]
35. Microperimetric correlations of autofluorescence and optical coherence tomography imaging in dry age-related macular degeneration.
Querques L; Querques G; Forte R; Souied EH
Am J Ophthalmol; 2012 Jun; 153(6):1110-5. PubMed ID: 22321805
[TBL] [Abstract][Full Text] [Related]
36. Ultra-wide-field fundus autofluorescence in multiple evanescent white dot syndrome.
Hashimoto H; Kishi S
Am J Ophthalmol; 2015 Apr; 159(4):698-706. PubMed ID: 25634532
[TBL] [Abstract][Full Text] [Related]
37. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.
Mavrikakis I; Sfikakis PP; Mavrikakis E; Rougas K; Nikolaou A; Kostopoulos C; Mavrikakis M
Ophthalmology; 2003 Jul; 110(7):1321-6. PubMed ID: 12867385
[TBL] [Abstract][Full Text] [Related]
38. SEQUENTIAL CHANGES IN HYDROXYCHLOROQUINE RETINOPATHY UP TO 20 YEARS AFTER STOPPING THE DRUG: Implications for Mild Versus Severe Toxicity.
Pham BH; Marmor MF
Retina; 2019 Mar; 39(3):492-501. PubMed ID: 30550532
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a follow-up protocol for patients on chloroquine and hydroxychloroquine treatment.
Sanabria MR; Toledo-Lucho SC
Arch Soc Esp Oftalmol; 2016 Jan; 91(1):10-4. PubMed ID: 26627497
[TBL] [Abstract][Full Text] [Related]
40. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy.
Lai TY; Chan WM; Li H; Lai RY; Lam DS
Am J Ophthalmol; 2005 Nov; 140(5):794-807. PubMed ID: 16310457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
